文献速递临床试验与 GCP流行病学与生物统计

螺内酯用于心血管不良结局高风险的慢性血液透析患者(ALCHEMIST):多中心、双盲、随机、安慰剂对照试验及更新Meta分析

Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
PubMed 文献 · Lancet · 2025-01-01

ALCHEMIST试验在法国、比利时和摩纳哥64个中心纳入644例心血管事件高风险的慢性血液透析合并肾衰竭患者,随机接受螺内酯或安慰剂。中位随访32.6个月,主要心血管不良事件发生率螺内酯组24% vs 安慰剂组24%(HR 1.00,95%CI 0.73-1.36,p=0.98),螺内酯未减少主要心血管事件。更新Meta分析显示盐皮质激素受体拮抗剂未降低全因或心血管死亡率,不支持该人群超说明书使用螺内酯。

要点

  • 慢性血液透析合并肾衰竭且心血管高风险患者中,螺内酯未减少主要心血管不良事件(HR 1.00,95%CI 0.73-1.36)。
  • 血钾>6 mmol/L高钾血症螺内酯组42% vs 安慰剂组41%(HR 1.12,95%CI 0.88-1.43)。
  • 更新Meta分析显示盐皮质激素受体拮抗剂未降低全因或心血管死亡率。

核心结论

  • 在慢性血液透析合并肾衰竭且心血管不良结局高风险的患者中,螺内酯未减少主要心血管事件的发生率。
  • 更新Meta分析显示盐皮质激素受体拮抗剂未降低全因或心血管死亡率,因此现有证据不支持该人群超说明书使用螺内酯。

研究设计与样本

  • ALCHEMIST为研究者发起的多中心、双盲、随机、安慰剂对照、事件驱动试验,在法国、比利时和摩纳哥64个中心开展。
  • 纳入18岁及以上慢性血液透析合并肾衰竭且至少有一种心血管合并症或危险因素的患者,先接受4周开放标签口服螺内酯25 mg隔日一次的导入期。
  • 导入后按1:1随机分配至口服螺内酯滴定至25 mg每日一次组或安慰剂组,随机序列由计算机生成并按中心分层、区组4或6内置换。
  • 主要终点为首次主要心血管不良事件时间,在意向治疗人群中分析;另对双盲随机对照试验进行更新Meta分析并纳入ALCHEMIST数据;试验注册号NCT01848639。

主要发现

  • 2013年6月13日至2020年11月24日筛查1442例,823例纳入试验,794例进入导入期,644例随机分配至螺内酯组(n=320)或安慰剂组(n=324),其中男性444例(69%)、女性200例(31%)。
  • 试验因申办方缺乏资金提前终止,中位随访32.6个月(IQR 17.3-48.4)。
  • 主要终点在螺内酯组320例中发生78例(24%)(每100患者年10.66次,95%CI 8.54-13.31),安慰剂组324例中发生79例(24%)(每100患者年10.70次,95%CI 8.59-13.35;HR 1.00,95%CI 0.73-1.36;p=0.98)。
  • 血钾>6 mmol/L的高钾血症在螺内酯组报告135例(42%),安慰剂组134例(41%)(HR 1.12,95%CI 0.88-1.43)。
  • Meta分析显示盐皮质激素受体拮抗剂未降低全因或心血管死亡率及非致死性心血管事件,也未增加高钾血症事件(血清钾浓度>6 mmol/L)的比值比。

临床怎么用

  • 作者结论指出,现有证据不支持在慢性血液透析合并肾衰竭且心血管不良结局高风险的患者中超说明书使用螺内酯。

局限性

  • 试验因申办方缺乏资金提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No pharmacological therapy has been shown with certainty to improve the cardiovascular prognosis in patients with kidney failure on chronic haemodialysis. We aimed to investigate the effects of the steroidal mineralocorticoid receptor antagonist spironolactone on cardiovascular outcomes in patients on haemodialysis who are at high risk of cardiovascular events. METHODS: ALCHEMIST was an investigator-initiated, multicentre, double-blind, randomised, placebo-controlled, event-driven trial conducted at 64 university hospitals, general hospitals, and non-profit or private practice dialysis centres in France, Belgium, and Monaco. Adult patients aged 18 years and older with kidney failure on chronic haemodialysis with at least one cardiovascular comorbidity or risk factor were enrolled into a 4-week run-in period on open-label oral spironolactone 25 mg every other day. Participants were randomly assigned (1:1) to oral spironolactone titrated to 25 mg per day or placebo. The randomisation sequence was computer generated and stratified by centre in blocks of 4 or 6, and permutation of treatments within each block. The random assignment was double-blinded. The primary endpoint was time to first major adverse cardiovascular event (cardiovascular death, non-fatal myocardial infarction, acute coronary syndrome, stroke, or hospitalisation for heart failure) and was analysed in the intention-to-treat population. We also performed an updated meta-analysis of double-blind, randomised controlled trials of mineralocorticoid receptor antagonists in patients on haemodialysis incorporating data from ALCHEMIST. The study was registered with ClinicalTrials.gov, NCT01848639. FINDINGS: Between June 13, 2013, and Nov 24, 2020, 1442 patients were locally screened for eligibility. 823 patients were included in the trial and 794 entered the run-in period. 644 patients were randomly assigned to spironolactone (n=320) or placebo (n=324). 444 (69%) patients were men and 200 (31%) were women. The trial was stopped prematurely due to lack of funding from the sponsor. Median follow-up was 32·6 months (IQR 17·3-48·4). The primary endpoint occurred in 78 (24%) of 320 patients in the spironolactone group (10·66 per 100 patient-years [95% CI 8·54-13·31]) and 79 (24%) of 324 patients in the placebo group (10·70 per 100 patient-years [8·59-13·35]; hazard ratio [HR] 1·00 [95% CI 0·73-1·36]; p=0·98). Hyperkalaemia above 6 mmol/L was reported in 135 (42%) patients in the spironolactone group and 134 (41%) in the placebo group (HR 1·12 [95% CI 0·88-1·43]). In the meta-analysis, mineralocorticoid receptor antagonists did not reduce all-cause or cardiovascular mortality or non-fatal cardiovascular events and did not increase the odds of hyperkalaemia events (serum potassium concentration >6 mmol/L). INTERPRETATION: In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events. The updated meta-analysis shows that mineralocorticoid receptor antagonists did not reduce all-cause or cardiovascular mortality. Therefore, off-label use of spironolactone in this setting is not supported by available evidence. FUNDING: French Ministry of Health.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Rossignol P, Zannad F, Massy Z, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet. 2025. PMID: 40818851. doi:10.1016/S0140-6736(25)01194-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。